Nomination Committee appointed in respect of AGM 2023 in Intervacc
Stockholm, November 11, 2022 - According to the principles for the appointment of the Nomination Committee in Intervacc AB (publ) adopted at the annual general meeting held on June 14th, 2022, the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of 31 August, along with the Chairman of the Board of Directors.
The composition of the Nomination Committee has now been established, and Intervacc today announced that the Nomination Committee in respect of the annual general meeting 2023 consists of the following persons who together represent approximately 23 percent of the number of shares and votes in the company based on the last known shareholder information at end September.
- Ulrika Enhörning, appointed by Swedbank Robur Fonder
- Lotta Sjöberg, appointed by Handelsbanken Fonder
- Thomas Ehlin, appointed by Fjärde AP-fonden
- Björn Sjöstrand, the Chairman of the Board
The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees, election of the chairman of the AGM, election of auditors (if applicable) and fee for the auditors, and proposals for rules for appointing the Nomination Committee.
The Nomination Committee’s proposals will be presented in the Notice to the annual general meeting 2023 and on Intervaccs’ web site, www.intervacc.com.
Shareholders who wishes to submit proposals to the Nomination Committee can do so by sending an e-mail to shareholders@intervacc.se (subject “Nomination Committee”) or by letter posted to Intervacc AB (publ), Attn: Intervacc Nomination Committee, Box 112, SE-129 22 Stockholm, Sweden.
For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com
The information was submitted for publication, through the agency of the contact person set out above on November 11, 2022, 16.00 CET.
About Intervacc
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10
